SAN DIEGO, Jan. 6, 2016 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
leadership members will present at two high-profile investment
conferences in January: Biotech Showcase 2016 and Noble Financial
Capital Markets 12th Annual Investor Conference.
Biotech Showcase 2016
Punit
Dhillon, President and CEO, and Robert H. Pierce, MD, Chief Scientific Officer,
will present a corporate overview at the Biotech Showcase 2016 on
Monday, January 11 at 11:00 AM PT on Track C – Mission II (Fourth
Floor) at Parc 55 San Francisco – Union Square in San Francisco. Please visit the "Investors"
section of OncoSec's website for webcast information:
http://ir.oncosec.com/.
Biotech Showcase is an investor and networking conference
devoted to providing biotechnology and life sciences companies with
an opportunity to present and meet with investors and
pharmaceutical executives during the course of one of the
industry's largest annual healthcare investor conferences. In its
eighth year, Biotech Showcase 2016 includes lunch plenary sessions
featuring top industry leaders and innovators speaking on industry
and time relevant topics, as well as presentations from both
private and public companies. For more information, please visit:
http://www.ebdgroup.com/bts/index.php.
Noble Financial Capital Markets 12th Annual Investor
Conference
Mr. Dhillon will present a corporate overview at
the Noble Financial Capital Markets 12th Annual Investor Conference
on Tuesday, January 19 at
3:30 PM ET in Room 1 at Club Med
Sandpiper Bay in Port St. Lucie,
Florida.
The Noble Financial Capital Markets 12th Annual Investor
Conference allows a diverse range of public and private companies
to provide formal presentations and request face-to-face meetings
with investors and corporate executives. The conference also
stimulates dialogue with Noble analysts, investment bankers, and
members of Noble's Scientific and Technology Advisory Boards during
networking events after the completion of formal presentations. For
more information, please visit:
https://nobleconference.com/home.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse™,
for the treatment of cancer. ImmunoPulse™ is designed to
enhance the local delivery and uptake of DNA-based immune-targeting
agents, such as IL-12. In Phase I and II clinical trials,
ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and
evidence of anti-tumor activity in the treatment of various skin
cancers as well as the potential to initiate a systemic immune
response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently
in Phase II development for several indications, including
metastatic melanoma, squamous cell carcinoma of the head and neck,
and triple-negative breast cancer. In addition to ImmunoPulse™
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse™ platform. For
more information, please visit www.oncosec.com.
Contact
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-prominent-investment-conferences-in-january-300200039.html
SOURCE OncoSec Medical Incorporated